Let’s start up with the current stock price of Protagonist Therapeutics Inc. (PTGX), which is $12.70 to be very precise. The Stock rose vividly during the last session to $12.78 after opening rate of $11.47 while the lowest price it went was recorded $11.21 before closing at $11.47.Recently in News on December 21, 2022, Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference. Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will offer a corporate presentation and host one-on-one meetings with investors at the 41st Annual J.P. Morgan Healthcare Conference, taking place January 9-12 in San Francisco, California. You can read further details here
Protagonist Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $13.11 on 01/12/23, with the lowest value was $10.62 for the same time period, recorded on 01/03/23.
Protagonist Therapeutics Inc. (PTGX) full year performance was -56.70%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Protagonist Therapeutics Inc. shares are logging -58.25% during the 52-week period from high price, and 83.79% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.91 and $30.42.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 2044838 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Protagonist Therapeutics Inc. (PTGX) recorded performance in the market was 16.41%, having the revenues showcasing 53.94% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 633.86M, as it employees total of 122 workers.
Market experts do have their say about Protagonist Therapeutics Inc. (PTGX)
During the last month, 5 analysts gave the Protagonist Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.95, with a change in the price was noted +3.99. In a similar fashion, Protagonist Therapeutics Inc. posted a movement of +45.81% for the period of last 100 days, recording 846,949 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PTGX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Protagonist Therapeutics Inc. (PTGX)
Raw Stochastic average of Protagonist Therapeutics Inc. in the period of last 50 days is set at 93.02%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.71%. In the last 20 days, the company’s Stochastic %K was 69.52% and its Stochastic %D was recorded 67.19%.
Bearing in mind the latest performance of Protagonist Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 16.41%. Additionally, trading for the stock in the period of the last six months notably improved by 29.59%, alongside a downfall of -56.70% for the period of the last 12 months. The shares increased approximately by 9.01% in the 7-day charts and went down by 29.99% in the period of the last 30 days. Common stock shares were driven by 53.94% during last recorded quarter.